Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?

Key Takeaways PFE shares have gained 11% YTD, trading above 50- and 200-day SMAs since early January.Pfizer's oncology and new products drove 2025 growth, with non-COVID revenues up 6%.PFE guides 2026 revenues of $59.5B-$62.5B and EPS of $2.80-$3.00, hurt by COVID decline and patent losses.Pfizer’s (PFE) stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.Image Source: Zacks Investment ResearchPfizer ...